Yes our therapy will be administered during the later phases...

Yes our therapy will be administered during the later phases when ARDS develops.

There will be no lack of patient for us to treat because:

1. These other earlier stage medicines (antivirals etc) will fail in a not so insignificant proportion of people and our therapy will be needed to treat the hyper-inflammation associated with ARDS, thus saving lives, reducing hospital stays, and as you say it is likely Rem-L will over 12 months improve respiratory function longer term and prevent re-hospitalisations (12 month data due out any time now).

2. Some people do not (or can not) take antivirals etc early enough to prevent the development of ARDS (which our therapy treats).

In short, there will be no lack of COVID patients to treat due to above reasons as they progress to ARDS.

NIH partnering the upcoming trial to provide data to support an Emergency Use Authorisation. This is not surprising because found to reduce death in under 65's in earlier trial and likely many more longer term benefits to be revealed soon.